Open access
Aug 2026
PCSK9 inhibitors for lipid-lowering treatment in patients with atherosclerotic cardiovascular disease: a health technology assessment
A health technology assessment framework is applied to systematically evaluate the use of PCSK9 inhibitors in patients with ASCVD and finds that evolocumab demonstrates relative advantages in lipid-lowering efficacy, cardiovascular outcomes, and economic value for patients with ASCVD.
Jing-Jing Lan, Yu-Lan Qiu, Shuaijian Wang et al.
· Frontiers in Cardiovascular... · 0 citations